314 related articles for article (PubMed ID: 35947229)
1. CD39 in the development and progression of pulmonary arterial hypertension.
Willcox A; Lee NT; Nandurkar HH; Sashindranath M
Purinergic Signal; 2022 Dec; 18(4):409-419. PubMed ID: 35947229
[TBL] [Abstract][Full Text] [Related]
2. Suppression of endothelial CD39/ENTPD1 is associated with pulmonary vascular remodeling in pulmonary arterial hypertension.
Helenius MH; Vattulainen S; Orcholski M; Aho J; Komulainen A; Taimen P; Wang L; de Jesus Perez VA; Koskenvuo JW; Alastalo TP
Am J Physiol Lung Cell Mol Physiol; 2015 May; 308(10):L1046-57. PubMed ID: 25820525
[TBL] [Abstract][Full Text] [Related]
3. Novel Molecular Mechanisms Involved in the Medical Treatment of Pulmonary Arterial Hypertension.
Martin de Miguel I; Cruz-Utrilla A; Oliver E; Escribano-Subias P
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835558
[TBL] [Abstract][Full Text] [Related]
4. Endothelial progenitor cells and pulmonary arterial hypertension.
Chen H; Strappe P; Chen S; Wang LX
Heart Lung Circ; 2014 Jul; 23(7):595-601. PubMed ID: 24680485
[TBL] [Abstract][Full Text] [Related]
5. Potential of the TRPM7 channel as a novel therapeutic target for pulmonary arterial hypertension.
Hiraishi K; Kurahara LH; Ishikawa K; Go T; Yokota N; Hu Y; Fujita T; Inoue R; Hirano K
J Smooth Muscle Res; 2022; 58(0):50-62. PubMed ID: 35944979
[TBL] [Abstract][Full Text] [Related]
6. Immune Cells in Pulmonary Arterial Hypertension.
Ni S; Ji T; Dong J; Chen F; Feng H; Zhao H; Chen D; Ma W
Heart Lung Circ; 2022 Jul; 31(7):934-943. PubMed ID: 35361533
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of the prolyl isomerase Pin1 improves endothelial function and attenuates vascular remodelling in pulmonary hypertension by inhibiting TGF-β signalling.
Kurakula K; Hagdorn QAJ; van der Feen DE; Vonk Noordegraaf A; Ten Dijke P; de Boer RA; Bogaard HJ; Goumans MJ; Berger RMF
Angiogenesis; 2022 Feb; 25(1):99-112. PubMed ID: 34379232
[TBL] [Abstract][Full Text] [Related]
8. An emerging strategy for targeted therapy of pulmonary arterial hypertension: Vasodilation plus vascular remodeling inhibition.
Hu L; Zhao C; Chen Z; Hu G; Li X; Li Q
Drug Discov Today; 2022 May; 27(5):1457-1463. PubMed ID: 35104622
[TBL] [Abstract][Full Text] [Related]
9. Evolving Concepts in Endothelial Pathobiology of Pulmonary Arterial Hypertension.
Cober ND; VandenBroek MM; Ormiston ML; Stewart DJ
Hypertension; 2022 Aug; 79(8):1580-1590. PubMed ID: 35582968
[TBL] [Abstract][Full Text] [Related]
10. NTP42, a novel antagonist of the thromboxane receptor, attenuates experimentally induced pulmonary arterial hypertension.
Mulvaney EP; Reid HM; Bialesova L; Bouchard A; Salvail D; Kinsella BT
BMC Pulm Med; 2020 Apr; 20(1):85. PubMed ID: 32252727
[TBL] [Abstract][Full Text] [Related]
11. Prevention of progression of pulmonary hypertension by the Nur77 agonist 6-mercaptopurine: role of BMP signalling.
Kurakula K; Sun XQ; Happé C; da Silva Goncalves Bos D; Szulcek R; Schalij I; Wiesmeijer KC; Lodder K; Tu L; Guignabert C; de Vries CJM; de Man FS; Vonk Noordegraaf A; Ten Dijke P; Goumans MJ; Bogaard HJ
Eur Respir J; 2019 Sep; 54(3):. PubMed ID: 31273046
[TBL] [Abstract][Full Text] [Related]
12. The Role of Sex in the Pathophysiology of Pulmonary Hypertension.
Docherty CK; Harvey KY; Mair KM; Griffin S; Denver N; MacLean MR
Adv Exp Med Biol; 2018; 1065():511-528. PubMed ID: 30051404
[TBL] [Abstract][Full Text] [Related]
13. Inflammatory Mechanisms in the Pathogenesis of Pulmonary Arterial Hypertension: Recent Advances.
Mercurio V; Cuomo A; Naranjo M; Hassoun PM
Compr Physiol; 2021 Apr; 11(2):1805-1829. PubMed ID: 33792903
[TBL] [Abstract][Full Text] [Related]
14. Treatment of pulmonary arterial hypertension: recent progress and a look to the future.
Humbert M; Sitbon O; Guignabert C; Savale L; Boucly A; Gallant-Dewavrin M; McLaughlin V; Hoeper MM; Weatherald J
Lancet Respir Med; 2023 Sep; 11(9):804-819. PubMed ID: 37591298
[TBL] [Abstract][Full Text] [Related]
15. Endothelial cells in the pathogenesis of pulmonary arterial hypertension.
Evans CE; Cober ND; Dai Z; Stewart DJ; Zhao YY
Eur Respir J; 2021 Sep; 58(3):. PubMed ID: 33509961
[TBL] [Abstract][Full Text] [Related]
16. Blockade of JAK2 protects mice against hypoxia-induced pulmonary arterial hypertension by repressing pulmonary arterial smooth muscle cell proliferation.
Zhang L; Wang Y; Wu G; Rao L; Wei Y; Yue H; Yuan T; Yang P; Xiong F; Zhang S; Zhou Q; Chen Z; Li J; Mo BW; Zhang H; Xiong W; Wang CY
Cell Prolif; 2020 Feb; 53(2):e12742. PubMed ID: 31943454
[TBL] [Abstract][Full Text] [Related]
17. Caspase-4/11-Mediated Pulmonary Artery Endothelial Cell Pyroptosis Contributes to Pulmonary Arterial Hypertension.
Wu Y; Pan B; Zhang Z; Li X; Leng Y; Ji Y; Sun K; Chen AF
Hypertension; 2022 Mar; 79(3):536-548. PubMed ID: 34984912
[TBL] [Abstract][Full Text] [Related]
18. Targeted therapies in pulmonary arterial hypertension.
Montani D; Chaumais MC; Guignabert C; Günther S; Girerd B; Jaïs X; Algalarrondo V; Price LC; Savale L; Sitbon O; Simonneau G; Humbert M
Pharmacol Ther; 2014 Feb; 141(2):172-91. PubMed ID: 24134901
[TBL] [Abstract][Full Text] [Related]
19. Role of Ion Channel Remodeling in Endothelial Dysfunction Induced by Pulmonary Arterial Hypertension.
Santos-Gomes J; Le Ribeuz H; Brás-Silva C; Antigny F; Adão R
Biomolecules; 2022 Mar; 12(4):. PubMed ID: 35454073
[TBL] [Abstract][Full Text] [Related]
20. [The cancer paradigm in pulmonary arterial hypertension: towards anti-remodeling therapies targeting metabolic dysfunction?].
Dumas SJ; Humbert M; Cohen-Kaminsky S
Biol Aujourdhui; 2016; 210(4):171-189. PubMed ID: 28327277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
